DE60315876D1 - Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz - Google Patents

Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz

Info

Publication number
DE60315876D1
DE60315876D1 DE60315876T DE60315876T DE60315876D1 DE 60315876 D1 DE60315876 D1 DE 60315876D1 DE 60315876 T DE60315876 T DE 60315876T DE 60315876 T DE60315876 T DE 60315876T DE 60315876 D1 DE60315876 D1 DE 60315876D1
Authority
DE
Germany
Prior art keywords
screening
sedative
compounds
potential
alleviation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60315876T
Other languages
English (en)
Other versions
DE60315876T2 (de
Inventor
Jens Mikkelsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of DE60315876D1 publication Critical patent/DE60315876D1/de
Application granted granted Critical
Publication of DE60315876T2 publication Critical patent/DE60315876T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60315876T 2002-11-28 2003-11-21 Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz Expired - Lifetime DE60315876T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200201840 2002-11-28
DK200201840 2002-11-28
PCT/EP2003/050860 WO2004048980A1 (en) 2002-11-28 2003-11-21 Method for screening for compounds as potential sedatives or anxiolytics

Publications (2)

Publication Number Publication Date
DE60315876D1 true DE60315876D1 (de) 2007-10-04
DE60315876T2 DE60315876T2 (de) 2008-05-21

Family

ID=32337947

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60315876T Expired - Lifetime DE60315876T2 (de) 2002-11-28 2003-11-21 Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz

Country Status (7)

Country Link
US (1) US20060013770A1 (de)
EP (1) EP1567869B1 (de)
JP (1) JP4426461B2 (de)
AT (1) ATE371193T1 (de)
AU (1) AU2003298302A1 (de)
DE (1) DE60315876T2 (de)
WO (1) WO2004048980A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102176826B (zh) * 2008-08-29 2014-08-20 康瑟特制药公司 取代的三唑并哒嗪衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU772947B2 (en) * 1999-01-27 2004-05-13 Merck Sharp & Dohme Limited Triazolo-pyridazine derivatives as ligands for GABA receptors
RU2251838C2 (ru) * 1999-07-15 2005-05-20 Рисерч Дивелопмент Фаундейшн Способ получения неприродной трансгенной мыши с дефицитом гена рецептора 2 кортиколиберина и ее использование
US7674463B1 (en) * 1999-07-15 2010-03-09 Research Development Foundation Method of inhibiting angiogenesis by administration of a corticotropin releasing factor receptor 2 agonist

Also Published As

Publication number Publication date
EP1567869B1 (de) 2007-08-22
EP1567869A1 (de) 2005-08-31
DE60315876T2 (de) 2008-05-21
AU2003298302A1 (en) 2004-06-18
ATE371193T1 (de) 2007-09-15
WO2004048980A1 (en) 2004-06-10
US20060013770A1 (en) 2006-01-19
JP2006513405A (ja) 2006-04-20
JP4426461B2 (ja) 2010-03-03

Similar Documents

Publication Publication Date Title
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
GEP20084550B (en) Substituted morpholine compounds for the treatment of central nervous system disorders
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
ATE545637T1 (de) Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
ATE461927T1 (de) Benzodiazepinsalze mit kurzzeitwirkung und polymorphe formen davon
CR8235A (es) Metodo para la promocion del crecimiento usando compuesto de amida
ATE429645T1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
DE602007009128D1 (de) Benzodiazepinsalze mit kurzzeitwirkung und polymorphe formen davon
ATE497809T1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
NO20055907L (no) Fremgangsmate for behandling av en angstforstyrrelse
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
PA8793201A1 (es) Pirimidinas bicíclicas fusinadas
DE602006020201D1 (de) Aerobes-anaerobes Verfahren zur Behandlung von organisch belasteten Abwässern
DE602006008583D1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
MX2009013205A (es) Derivados de pirazoloquinolina urea terapeuticos.
HK1142775A1 (en) Therapeutic pyrazoloquinoline derivatives
MX2009013197A (es) Derivados terapeuticos de pirazolonaftiridina.
DE60315876D1 (de) Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz
NO20090972L (no) Pyrazolo[1,5-A]pyrimidiner, fremgangsmater, anvendelser og sammensetninger
MXPA06000700A (es) Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition